Supernus Pharmaceuticals (SUPN) Stock Forecast, Price Target & Predictions
SUPN Stock Forecast
Supernus Pharmaceuticals stock forecast is as follows: an average price target of $38.00 (represents a 9.51% upside from SUPN’s last price of $34.70) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
SUPN Price Target
The average price target for Supernus Pharmaceuticals (SUPN) is $38.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $40.00 to $36.00. This represents a potential 9.51% upside from SUPN's last price of $34.70.
SUPN Analyst Ratings
According to 3 Wall Street analysts, Supernus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for SUPN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Supernus Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | David Amsellem | Piper Sandler | $36.00 | $33.49 | 7.49% | 3.75% |
| May 24, 2024 | David Amsellem | Piper Sandler | $41.00 | $27.84 | 47.24% | 18.16% |
| Apr 08, 2024 | Irene Buhalo | Jefferies | $40.00 | $32.27 | 23.97% | 15.27% |
| Apr 08, 2024 | Annabel Samimy | Stifel Nicolaus | $38.00 | $32.27 | 17.77% | 9.51% |
The latest Supernus Pharmaceuticals stock forecast, released on Sep 11, 2024 by David Amsellem from Piper Sandler, set a price target of $36.00, which represents a 7.49% increase from the stock price at the time of the forecast ($33.49), and a 3.75% increase from SUPN last price ($34.70).
Supernus Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $36.00 | $38.75 |
| Last Closing Price | $34.70 | $34.70 | $34.70 |
| Upside/Downside | -100.00% | 3.75% | 11.67% |
In the current month, the average price target of Supernus Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Supernus Pharmaceuticals's last price of $34.70. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 18, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 18, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Sep 10, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
| May 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 08, 2024 | Jefferies | Buy | Buy | Hold |
Supernus Pharmaceuticals's last stock rating was published by Cowen & Co. on Oct 18, 2024. The company gave SUPN a "Buy" rating, the same as its previous rate.
Supernus Pharmaceuticals Financial Forecast
Supernus Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $153.88M | $135.56M | $153.76M | $167.33M | $177.35M | $170.05M | $152.51M | $159.05M | $148.46M | $141.33M | $130.93M | $143.56M | $155.13M | $126.73M | $94.98M | $100.45M | $102.14M | $104.69M | $85.47M | $90.43M | $57.58M |
| Avg Forecast | $161.15M | $156.70M | $151.20M | $141.95M | $150.24M | $157.35M | $148.83M | $145.83M | $155.03M | $146.17M | $143.63M | $139.02M | $180.33M | $172.48M | $164.13M | $153.91M | $155.00M | $142.12M | $135.42M | $129.10M | $146.19M | $131.00M | $98.77M | $83.45M | $107.03M | $108.67M | $109.29M | $102.15M | $60.90M | $66.67M |
| High Forecast | $161.15M | $156.70M | $151.20M | $141.95M | $150.24M | $161.74M | $148.83M | $145.83M | $158.10M | $146.19M | $143.63M | $139.02M | $180.33M | $172.48M | $164.13M | $153.91M | $155.00M | $142.12M | $135.42M | $129.10M | $146.19M | $131.00M | $98.77M | $83.45M | $107.03M | $108.67M | $109.29M | $102.15M | $73.08M | $80.00M |
| Low Forecast | $161.15M | $156.70M | $151.20M | $141.95M | $150.24M | $154.24M | $148.83M | $145.83M | $152.31M | $146.15M | $143.63M | $139.02M | $180.33M | $172.48M | $164.13M | $153.91M | $155.00M | $142.12M | $135.42M | $129.10M | $146.19M | $131.00M | $98.77M | $83.45M | $107.03M | $108.67M | $109.29M | $102.15M | $48.72M | $53.33M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.05% | 0.94% | 1.11% | 0.93% | 1.03% | 1.04% | 0.99% | 1.03% | 1.04% | 1.04% | 1.01% | 0.98% | 1.18% | 1.28% | 1.14% | 0.94% | 0.94% | 0.96% | 0.84% | 1.48% | 0.86% |
Supernus Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 3 analysts is $155.03M, with a low forecast of $152.31M, and a high forecast of $158.10M. SUPN's average Quarter revenue forecast represents a 0.75% increase compared to the company's last Quarter revenue of $153.88M (Sep 23).
Supernus Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $31.29M | $-17.59M | $28.84M | $55.03M | $22.41M | $34.52M | $37.97M | $20.69M | $41.56M | $43.32M | $23.62M | $51.31M | $66.38M | $56.34M | $36.52M | $48.41M | $45.70M | $50.08M | $32.67M | $34.31M | $18.01M |
| Avg Forecast | $46.10M | $44.83M | $43.26M | $40.61M | $42.98M | $45.01M | $42.58M | $43.62M | $44.35M | $41.82M | $41.09M | $39.65M | $56.11M | $49.34M | $46.95M | $36.05M | $44.34M | $40.66M | $38.74M | $32.77M | $41.82M | $37.48M | $28.26M | $22.96M | $30.62M | $31.09M | $31.26M | $41.70M | $19.44M | $20.47M |
| High Forecast | $46.10M | $44.83M | $43.26M | $40.61M | $42.98M | $46.27M | $42.58M | $52.34M | $45.23M | $41.82M | $41.09M | $47.58M | $67.34M | $49.34M | $46.95M | $43.26M | $44.34M | $40.66M | $38.74M | $39.32M | $41.82M | $37.48M | $28.26M | $27.55M | $30.62M | $31.09M | $31.26M | $50.04M | $23.33M | $24.56M |
| Low Forecast | $46.10M | $44.83M | $43.26M | $40.61M | $42.98M | $44.13M | $42.58M | $34.89M | $43.57M | $41.81M | $41.09M | $31.72M | $44.89M | $49.34M | $46.95M | $28.84M | $44.34M | $40.66M | $38.74M | $26.22M | $41.82M | $37.48M | $28.26M | $18.36M | $30.62M | $31.09M | $31.26M | $33.36M | $15.55M | $16.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.75% | -0.43% | 0.73% | 0.98% | 0.45% | 0.74% | 1.05% | 0.47% | 1.02% | 1.12% | 0.72% | 1.23% | 1.77% | 1.99% | 1.59% | 1.58% | 1.47% | 1.60% | 0.78% | 1.76% | 0.88% |
3 analysts predict SUPN's average Quarter EBITDA for Dec 23 to be $44.35M, with a high of $45.23M and a low of $43.57M. This is 41.74% upper than Supernus Pharmaceuticals's previous annual EBITDA (Sep 23) of $31.29M.
Supernus Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $-15.98M | $-831.00K | $16.95M | $25.48M | $1.75M | $7.87M | $25.62M | $2.44M | $21.56M | $23.73M | $5.69M | $30.77M | $40.00M | $34.67M | $21.52M | $33.13M | $28.86M | $32.73M | $18.34M | $26.35M | $10.30M |
| Avg Forecast | $28.14M | $24.52M | $21.45M | $17.83M | $18.20M | $24.70M | $21.73M | $10.52M | $30.83M | $278.62K | $11.70M | $9.56M | $33.65M | $19.88M | $16.16M | $8.69M | $16.16M | $15.46M | $13.51M | $7.90M | $31.34M | $19.36M | $24.38M | $13.53M | $32.99M | $34.10M | $33.35M | $23.41M | $14.93M | $11.70M |
| High Forecast | $28.14M | $24.52M | $21.45M | $17.83M | $18.20M | $27.24M | $21.73M | $12.62M | $33.09M | $278.62K | $11.70M | $11.47M | $40.38M | $19.88M | $16.16M | $10.43M | $16.16M | $15.46M | $13.51M | $9.48M | $31.34M | $19.36M | $24.38M | $16.23M | $32.99M | $34.10M | $33.35M | $28.10M | $17.92M | $14.04M |
| Low Forecast | $28.14M | $24.52M | $21.45M | $17.83M | $18.20M | $22.17M | $21.73M | $8.41M | $28.58M | $278.62K | $11.70M | $7.65M | $26.92M | $19.88M | $16.16M | $6.95M | $16.16M | $15.46M | $13.51M | $6.32M | $31.34M | $19.36M | $24.38M | $10.82M | $32.99M | $34.10M | $33.35M | $18.73M | $11.95M | $9.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | -57.34% | -0.07% | 1.77% | 0.76% | 0.09% | 0.49% | 2.95% | 0.15% | 1.39% | 1.76% | 0.72% | 0.98% | 2.07% | 1.42% | 1.59% | 1.00% | 0.85% | 0.98% | 0.78% | 1.76% | 0.88% |
Supernus Pharmaceuticals's average Quarter net income forecast for Jun 23 is $11.70M, with a range of $11.70M to $11.70M. SUPN's average Quarter net income forecast represents a -30.95% decrease compared to the company's last Quarter net income of $16.95M (Mar 23).
Supernus Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $82.70M | $86.78M | $85.60M | $73.97M | $112.31M | $100.48M | $90.46M | $101.73M | $72.03M | $69.53M | $61.46M | $56.30M | $54.66M | $48.10M | $42.88M | $35.73M | $40.65M | $41.08M | $40.97M | $36.85M | $28.24M |
| Avg Forecast | $78.44M | $76.27M | $73.59M | $69.09M | $73.13M | $76.59M | $72.44M | $113.50M | $75.46M | $71.15M | $69.91M | $103.18M | $61.57M | $83.95M | $79.89M | $93.80M | $75.44M | $69.17M | $65.91M | $85.27M | $71.16M | $63.76M | $48.07M | $26.95M | $52.09M | $52.89M | $53.19M | $52.30M | $20.88M | $32.09M |
| High Forecast | $78.44M | $76.27M | $73.59M | $69.09M | $73.13M | $78.72M | $72.44M | $136.20M | $76.95M | $71.15M | $69.91M | $123.81M | $73.89M | $83.95M | $79.89M | $112.56M | $75.44M | $69.17M | $65.91M | $102.33M | $71.16M | $63.76M | $48.07M | $32.34M | $52.09M | $52.89M | $53.19M | $62.76M | $25.06M | $38.51M |
| Low Forecast | $78.44M | $76.27M | $73.59M | $69.09M | $73.13M | $75.07M | $72.44M | $90.80M | $74.13M | $71.14M | $69.91M | $82.54M | $49.26M | $83.95M | $79.89M | $75.04M | $75.44M | $69.17M | $65.91M | $68.22M | $71.16M | $63.76M | $48.07M | $21.56M | $52.09M | $52.89M | $53.19M | $41.84M | $16.70M | $25.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.16% | 1.24% | 0.83% | 1.20% | 1.34% | 1.26% | 0.96% | 1.35% | 1.04% | 1.05% | 0.72% | 0.79% | 0.86% | 1.00% | 1.59% | 0.69% | 0.77% | 0.77% | 0.78% | 1.76% | 0.88% |
Supernus Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $75.46M, based on 3 Wall Street analysts, with a range of $74.13M to $76.95M. The forecast indicates a -8.76% fall compared to SUPN last annual SG&A of $82.70M (Sep 23).
Supernus Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 10 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.29 | $-0.02 | $0.31 | $0.47 | $0.03 | $0.15 | $0.48 | $0.05 | $0.41 | $0.45 | $0.11 | $0.58 | $0.76 | $0.66 | $0.41 | $0.63 | $0.55 | $0.62 | $0.35 | $0.51 | $0.21 |
| Avg Forecast | $0.51 | $0.44 | $0.39 | $0.32 | $0.33 | $0.44 | $0.39 | $0.26 | $0.55 | $0.01 | $0.21 | $0.31 | $0.67 | $0.36 | $0.29 | $0.32 | $0.29 | $0.28 | $0.24 | $0.29 | $0.56 | $0.35 | $0.44 | $0.27 | $0.59 | $0.61 | $0.60 | $0.48 | $0.19 | $0.25 |
| High Forecast | $0.51 | $0.44 | $0.39 | $0.32 | $0.33 | $0.49 | $0.39 | $0.26 | $0.59 | $0.01 | $0.21 | $0.31 | $0.67 | $0.36 | $0.29 | $0.32 | $0.29 | $0.28 | $0.24 | $0.29 | $0.56 | $0.35 | $0.44 | $0.27 | $0.59 | $0.61 | $0.60 | $0.48 | $0.22 | $0.30 |
| Low Forecast | $0.51 | $0.44 | $0.39 | $0.32 | $0.33 | $0.40 | $0.39 | $0.26 | $0.51 | $0.01 | $0.21 | $0.31 | $0.67 | $0.36 | $0.29 | $0.32 | $0.29 | $0.28 | $0.24 | $0.29 | $0.56 | $0.35 | $0.44 | $0.27 | $0.59 | $0.61 | $0.60 | $0.48 | $0.15 | $0.20 |
| Surprise % | - | - | - | - | - | - | - | - | - | -58.00% | -0.07% | 1.01% | 0.70% | 0.08% | 0.52% | 1.51% | 0.16% | 1.48% | 1.86% | 0.38% | 1.03% | 2.19% | 1.51% | 1.52% | 1.06% | 0.90% | 1.04% | 0.74% | 2.68% | 0.84% |
According to 1 Wall Street analysts, Supernus Pharmaceuticals's projected average Quarter EPS for Jun 23 is $0.21, with a low estimate of $0.21 and a high estimate of $0.21. This represents a -32.26% decrease compared to SUPN previous annual EPS of $0.31 (Mar 23).
Supernus Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences | $16.45 | $40.00 | 143.16% | Hold |
| EVO | Evotec SE | $4.40 | $8.00 | 81.82% | Buy |
| ANIP | ANI Pharmaceuticals | $56.01 | $79.00 | 41.05% | Buy |
| COLL | Collegium Pharmaceutical | $32.72 | $41.50 | 26.83% | Buy |
| PBH | Prestige Consumer Healthcare | $73.79 | $82.00 | 11.13% | Buy |
| SUPN | Supernus Pharmaceuticals | $34.70 | $38.00 | 9.51% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $22.37 | $18.67 | -16.54% | Buy |
SUPN Forecast FAQ
Is Supernus Pharmaceuticals a good buy?
Yes, according to 3 Wall Street analysts, Supernus Pharmaceuticals (SUPN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of SUPN's total ratings.
What is SUPN's price target?
Supernus Pharmaceuticals (SUPN) average price target is $38 with a range of $36 to $40, implying a 9.51% from its last price of $34.7. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Supernus Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for SUPN stock, the company can go up by 9.51% (from the last price of $34.7 to the average price target of $38), up by 15.27% based on the highest stock price target, and up by 3.75% based on the lowest stock price target.
Can Supernus Pharmaceuticals stock reach $50?
SUPN's average twelve months analyst stock price target of $38 does not support the claim that Supernus Pharmaceuticals can reach $50 in the near future.
What are Supernus Pharmaceuticals's analysts' financial forecasts?
Supernus Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $602.25M (high $606.64M, low $599.14M), average EBITDA is $174.19M (high $184.17M, low $164.58M), average net income is $75.16M (high $79.79M, low $70.52M), average SG&A $335.65M (high $360.48M, low $311.44M), and average EPS is $1.42 (high $1.47, low $1.38). SUPN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $611M (high $611M, low $611M), average EBITDA is $174.8M (high $174.8M, low $174.8M), average net income is $91.95M (high $91.95M, low $91.95M), average SG&A $297.39M (high $297.39M, low $297.39M), and average EPS is $1.65 (high $1.65, low $1.65).
Did the SUPN's actual financial results beat the analysts' financial forecasts?
Based on Supernus Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $607.52M, beating the average analysts forecast of $583.86M by 4.05%. Apple's EBITDA was $-5.269M, missing the average prediction of $166.91M by -103.16%. The company's net income was $1.32M, missing the average estimation of $52.37M by -97.49%. Apple's SG&A was $336.36M, beating the average forecast of $319.69M by 5.21%. Lastly, the company's EPS was $0, missing the average prediction of $1.07 by -100.00%. In terms of the last quarterly report (Sep 2023), Supernus Pharmaceuticals's revenue was $153.88M, beating the average analysts' forecast of $146.17M by 5.27%. The company's EBITDA was $31.29M, missing the average prediction of $41.82M by -25.17%. Supernus Pharmaceuticals's net income was $-15.976M, missing the average estimation of $278.62K by -5833.95%. The company's SG&A was $82.7M, beating the average forecast of $71.15M by 16.24%. Lastly, the company's EPS was $-0.29, missing the average prediction of $0.005 by -5900.00%